Compare Stocks: EPRX, IMCR, LKFT, and SNDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$8.40 +12.0%	$6.68	$5.15 ▼ $9.32	$487.64M	1.07	357,777 shs	3.52 million shs
IMCR Immunocore	$36.13 -3.8%	$34.49	$27.56 ▼ $40.71	$1.93B	0.74	370,881 shs	231,712 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$28.49 -1.8%	$28.72	$25.68 ▼ $37.78	$1.91B	0.28	259,819 shs	208,175 shs
SNDX Syndax Pharmaceuticals	$20.56 -0.6%	$20.96	$12.99 ▼ $25.59	$1.83B	0.37	1.22 million shs	1.36 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	+12.00%	+25.75%	+29.63%	+41.18%	+55.56%
IMCR Immunocore	-3.83%	-1.34%	+8.53%	+27.71%	+2.44%
LKFT Lakefront Biotherapeutics American Depositary Shares	-1.83%	-1.35%	+9.24%	+1.68%	-8.86%
SNDX Syndax Pharmaceuticals	-0.58%	+5.22%	+3.21%	+18.57%	+27.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPRX Eupraxia Pharmaceuticals	$8.40 +12.0%	$6.68	$5.15 ▼ $9.32	$487.64M	1.07	357,777 shs	3.52 million shs
IMCR Immunocore	$36.13 -3.8%	$34.49	$27.56 ▼ $40.71	$1.93B	0.74	370,881 shs	231,712 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$28.49 -1.8%	$28.72	$25.68 ▼ $37.78	$1.91B	0.28	259,819 shs	208,175 shs
SNDX Syndax Pharmaceuticals	$20.56 -0.6%	$20.96	$12.99 ▼ $25.59	$1.83B	0.37	1.22 million shs	1.36 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPRX Eupraxia Pharmaceuticals	+12.00%	+25.75%	+29.63%	+41.18%	+55.56%
IMCR Immunocore	-3.83%	-1.34%	+8.53%	+27.71%	+2.44%
LKFT Lakefront Biotherapeutics American Depositary Shares	-1.83%	-1.35%	+9.24%	+1.68%	-8.86%
SNDX Syndax Pharmaceuticals	-0.58%	+5.22%	+3.21%	+18.57%	+27.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPRX Eupraxia Pharmaceuticals	2.89	Moderate Buy	$18.00	114.29% Upside
IMCR Immunocore	2.69	Moderate Buy	$56.38	56.03% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.33	Hold	$30.67	7.64% Upside
SNDX Syndax Pharmaceuticals	2.83	Moderate Buy	$42.30	105.74% Upside

Current Analyst Ratings Breakdown

Latest EPRX, IMCR, LKFT, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/24/2026	IMCR Immunocore	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$37.00 ➝ $33.00
8/21/2026	IMCR Immunocore	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$50.00
8/21/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$30.00 ➝ $26.00
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$28.00 ➝ $26.00
8/11/2026	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
8/7/2026	IMCR Immunocore	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$43.00
8/5/2026	SNDX Syndax Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.54 per share	N/A
IMCR Immunocore	$400.02M	4.65	N/A	N/A	$8.15 per share	4.43
LKFT Lakefront Biotherapeutics American Depositary Shares	$990.57M	1.90	$0.71 per share	39.97	$57.58 per share	0.49
SNDX Syndax Pharmaceuticals	$172.35M	10.57	N/A	N/A	$0.17 per share	120.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.02	N/A	N/A	N/A	N/A	-63.97%	-43.32%	11/3/2026 (Estimated)
IMCR Immunocore	-$35.51M	-$0.37	N/A	144.52	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)

Latest EPRX, IMCR, LKFT, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.04	+$1.0072	$0.04	$7.29 million	$15.47 million
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPRX Eupraxia Pharmaceuticals	0.02	16.00	16.00
IMCR Immunocore	0.94	4.47	4.44
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	32.84	32.72
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPRX Eupraxia Pharmaceuticals	N/A
IMCR Immunocore	84.50%
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
EPRX Eupraxia Pharmaceuticals	N/A
IMCR Immunocore	10.10%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
SNDX Syndax Pharmaceuticals	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPRX Eupraxia Pharmaceuticals	29	65.02 million	N/A	N/A
IMCR Immunocore	320	51.50 million	46.30 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
SNDX Syndax Pharmaceuticals	110	88.61 million	84.36 million	Optionable

EPRX, IMCR, LKFT, and SNDX Headlines

Recent News About These Companies

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

September 4 at 4:01 PM | globenewswire.com

Pale Fire Capital SE Sells 158,910 Shares of Syndax Pharmaceuticals, Inc. $SNDX

September 3 at 6:15 AM | marketbeat.com

Alyeska Investment Group L.P. Acquires Shares of 308,507 Syndax Pharmaceuticals, Inc. $SNDX

September 2 at 3:03 AM | marketbeat.com

Syndax Announces Participation in September Investor Conferences

September 1, 2026 | globenewswire.com

Man Group plc Takes $4.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX

August 31, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New $22.74 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX

August 31, 2026 | marketbeat.com

Palo Alto Investors LP Acquires Shares of 864,986 Syndax Pharmaceuticals, Inc. $SNDX

August 28, 2026 | marketbeat.com

Deutsche Bank AG Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX

August 28, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Invests $1.65 Million in Syndax Pharmaceuticals, Inc. $SNDX

August 27, 2026 | marketbeat.com

Ieq Capital LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX

August 27, 2026 | marketbeat.com

Trails Edge Capital Partners LP Buys Shares of 1,110,000 Syndax Pharmaceuticals, Inc. $SNDX

August 26, 2026 | marketbeat.com

Elmind Capital LP Buys Shares of 1,855,000 Syndax Pharmaceuticals, Inc. $SNDX

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX

August 25, 2026 | marketbeat.com

Algert Global LLC Has $22.98 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDX

August 25, 2026 | marketbeat.com

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

August 24, 2026 | invezz.comI

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts

August 20, 2026 | marketbeat.com

GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX

August 17, 2026 | marketbeat.com

Syndax (SNDX) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co.

August 11, 2026 | marketbeat.com

Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX

August 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, IMCR, LKFT, and SNDX Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

$8.40 +0.90 (+12.00%)

As of 09/4/2026 04:00 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Immunocore NASDAQ:IMCR

$36.13 -1.44 (-3.83%)

As of 09/4/2026 04:00 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$28.49 -0.53 (-1.83%)

As of 09/4/2026 04:00 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Syndax Pharmaceuticals NASDAQ:SNDX

$20.56 -0.12 (-0.58%)

As of 09/4/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, IMCR, LKFT, and SNDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, IMCR, LKFT, and SNDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, IMCR, LKFT, and SNDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, IMCR, LKFT, and SNDX Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

Immunocore NASDAQ:IMCR

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, IMCR, LKFT, and SNDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, IMCR, LKFT, and SNDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, IMCR, LKFT, and SNDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, IMCR, LKFT, and SNDX Company Descriptions

Eupraxia Pharmaceuticals NASDAQ:EPRX

Immunocore NASDAQ:IMCR

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools